Comparison of silver-enhanced in situ hybridization and fluorescence in situ hybridization for HER2 gene status in breast carcinomas

Journal of Breast Cancer

Volumn 12, Issue 4, 2009, Pages 235-240

  Kang, Jun ^a   Kwon, Gui Young ^b   Lee, Young Hee ^c   Gong, Gyungyub ^c  

^a Military Manpower Administration   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

Breast neoplasms; erbB 2 receptor; In situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CARCINOMA; CHROMOSOME 17; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; TISSUE MICROARRAY; TISSUE SECTION;

EID: 74849094396     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2009.12.4.235     Document Type: Article

References (13)

1. Sahin AA. Biologic and clinical significance of HER2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 2000;7:158-66.
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43.
5. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
6. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
7. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Ru-schoff J, Gutjahr T, et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol 2007;20:584-91.
8. Cell Markers and Cytogenetics Committees College Of American Pathologists. Clinical laboratory assays for HER2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803-8.
9. Dietel M, Ellis IO, Ho-fler H, Kreipe H, Moch H, Dankof A, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19-25.
10. Carbone A, Botti G, Gloghini A, Simone G, Truini M, Curcio MP, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 2008;10:527-36.
11. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
12. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 2004;35:647-53.
13. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER2/neu oncogene in breast cancer. Am J Clin Pathol 2003;119:381-7.